SCHEMBL31347764

SCHEMBL31347764

CC(=O)Nc1ccc(Br)c(F)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.53
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA9 Q16790 4/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
EPHX1 P07099 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KIF11 P52732 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
IDO1 P14902 1/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1693205 1.00 RXFP1 (0.53) RXFP1CA1CA2CA9HDAC1
SCHEMBL11932852 0.86 RXFP1 (0.53) RXFP1CA1CA2CA9HDAC1
SCHEMBL12596677 0.85 RXFP1 (0.56) RXFP1CA1CA2CA9HDAC1
SCHEMBL30521190 0.85 RXFP1 (0.56) RXFP1CA1CA2CA9HDAC1
SCHEMBL1601224 0.83 RXFP1 (0.58) RXFP1CA1CA2CA9HDAC1
SCHEMBL10472153 0.81 HDAC1 (0.47) RXFP1CA1CA2CA9HDAC1
SCHEMBL15594102 0.81 ALDH1A1 (0.50) RXFP1CA1CA2CA9HDAC1
SCHEMBL15594109 0.79 ALDH1A1 (0.45) CA1CA2CA9HDAC1HDAC6
SCHEMBL13715560 0.79 CA1 (0.44) RXFP1CA1CA2CA9HDAC1
SCHEMBL2429572 0.79 RXFP1 (0.53) RXFP1CA1CA2CA9HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365682-B2 Process to make GLP1 RA and intermediates therefor ELI LILLY AND COMPANY (US) 2025-07-22 US disclosed
US-20250042899-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365682-B2 Process to make GLP1 RA and intermediates therefor GLP1R, GIPR, NPY4R RXFP1 7/4885CA1 2056/4885CA2 2493/4885
US-20250042899-A1 PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR GLP1R, GIPR, NPY4R RXFP1 7/4885CA1 2056/4885CA2 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.